XML 34 R22.htm IDEA: XBRL DOCUMENT v3.25.3
EARNINGS PER SHARE
 9 Months Ended
Sep. 30, 2025
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
The numerator for both basic and diluted earnings per share (EPS) is net income (loss) attributable to Baxter stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units (RSUs) and performance share units (PSUs) is reflected in the denominator for diluted EPS using the treasury stock method.
The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.
Three Months Ended September 30,Nine Months Ended September 30,
(in millions)2025202420252024
Income (loss) from continuing operations$(51)$61 $135 $162 
Less: Net income attributable to noncontrolling interests included in continuing operations— — — — 
Income (loss) from continuing operations attributable to Baxter stockholders(51)61 135 162 
Income (loss) from discontinued operations5 83 36 (290)
Less: Net income attributable to noncontrolling interests included in discontinued operations— 4 — 9 
Income (loss) from discontinued operations attributable to Baxter stockholders5 79 36 (299)
Net income (loss) attributable to Baxter stockholders$(46)$140 $171 $(137)
The following table is a reconciliation of basic shares and diluted shares.
Three Months Ended September 30,Nine Months Ended September 30,
(in millions)2025202420252024
Basic shares514 510 513 509 
Effect of dilutive securities— 2 1 2 
Diluted shares514 512 514 511 
Basic and diluted shares are the same for three months ended September 30, 2025 due to our loss from continuing operations attributable to Baxter stockholders. The effect of dilutive securities includes unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excludes 22 million and 20 million shares issuable under equity awards for the three and nine months ended September 30, 2025, respectively, and 18 million and 19 million shares issuable under equity awards for the three and nine months ended September 30, 2024, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS.